BioPharma Credit (LSE:BPCR) ROCE %: % (As of Dec. 2025)


LSE:BPCR BioPharma Credit PLC LSE:BPCR
49 GF Score
Price $0.96
GF Value $0.97
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is BioPharma Credit ROCE %?

BioPharma Credit LSE:BPCR +0.63% 49 ROCE % is % as of Dec. 2025. GuruFocus rates LSE:BPCR with a GF Score™ of 49/100 and a GF Value™ of $0.97 (Fairly Valued). The stock has 2 warning signs investors should review.

ROCE % does not apply to banks and insurance companies.

LSE:BPCR
49GF Score
BioPharma Credit PLC LSE:BPCR
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of % mean?
BioPharma Credit (LSE:BPCR) has a ROCE % of % as of Dec. 2025.
Is BioPharma Credit's ROCE % too high?
BioPharma Credit's current ROCE % is %. Overall, BioPharma Credit has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioPharma Credit's ROCE % compare to BLK and BX?
BioPharma Credit's ROCE % of % can be compared against companies in the Asset Management industry. The industry median ROCE % is 4.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for an Asset Management company?
The median ROCE % among Asset Management companies is 4.46, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Asset Management industry, the median ROCE % is 4.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioPharma Credit's current ROCE % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioPharma Credit stock overvalued right now?
Based on GuruFocus' analysis, BioPharma Credit (LSE:BPCR) is currently considered Fairly Valued. The stock's GF Value™ is $0.97, compared to a current price of $0.96 — trading 1% below its estimated fair value. The current ROCE % is %. BioPharma Credit's overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For BioPharma Credit (LSE:BPCR), the current ROCE % is % as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioPharma Credit (LSE:BPCR) Overvalued in 2026?

Based on GuruFocus' analysis, BioPharma Credit stock appears to be undervalued. The current stock price of $0.96 is trading 1% below its estimated GF Value™ of $0.97. GuruFocus considers BioPharma Credit to be Fairly Valued.

Key valuation signals for LSE:BPCR:

  • ROCE %: %
  • GF Value™: $0.97 vs. price of $0.96 (1% below fair value)
  • GF Score™: 49/100 with 2 warning signs

No single metric tells the full story. See the LSE:BPCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioPharma Credit Business Description

Address c/o MUFG Corporate Governance Limited, 51 Lime Street, 19th Floor, London, GBR, EC3M 7DQ
BioPharma Credit PLC is an investment trust. Its investment objective is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The trust focuses on achieving its investment objective through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt, and credit linked notes. Its diversified investment portfolio is mainly secured by approved life sciences products and the cash flows derived from their sales.
49GF Score

Get the complete analysis for LSE:BPCR

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.96
Price
$0.97
GF Value